Lobbying Filing Details

Total Spending

$1,580,000

Activities

6

Lobbyists

11

Gov't Entities

48

Filing Information
Filing UUID:
9dd3d5ea-8edb-4ce8-b780-368849b92451
Type:
Q4 - 4th Quarter - Report
Period:
2019 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 21, 2020 at 6:13 PM
Income:
$0
Expenses:
$1,580,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (6)
Activity 1
Budget/Appropriations

FDA Funding.
H.R.1865: Further Consolidated Appropriations Act, 2020.
Section 605 of H.R.1865: Further Consolidated Appropriations Act, 2020.
Public Law 115-123: Bipartisan Budget Act of 2018.
Public Law 115-141: Consolidated Appropriations Act of 2018.

Lobbyists (7)
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Commerce, Dept of (DOC)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 2
Copyright/Patent/Trademark

Inter Partes Review (IPR) Process.
Patent Settlements.
Patent Abuse.
Accelerating the Patent Dance.
BPCIA Patent Dance.
H.R.3666: STRONGER Patents Act of 2019.
Section 101 of the Patent Act.
Patent Examination and Quality Improvement Act (Bill number not yet assigned).
S.1416: Affordable Prescriptions for Patients Act of 2019.
H.R.3199: Terminating the Extension of Rights Misappropriated (TERM) Act of 2019.
H.R.3812/S.1209: Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act.

Lobbyists (6)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Commerce, Dept of (DOC)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 3
Medicare/Medicaid

Medicare Part D Program and Generic Drugs.
Medicare Reimbursement for Biosimilars.
Medicaid Rebate Penalty.
Medicare Part D Low Income Subsidy (LIS) Program.
Medicare Part D Coverage Gap Discount Program.
Medicare Shared Savings Program.
S.1895: Lower Health Care Costs Act.

Lobbyists (7)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JOSEPH STEWART
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Commerce, Dept of (DOC)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 4
Pharmacy

Implementation of Food and Drug Administration Reauthorization Act (FDARA).
Generic Drug User Fee Amendments (GDUFA).
Biosimilar User Fee Act (BsUFA).
Labeling of Generic Drugs and Biosimilars.
Country of Manufacture Labeling.
H.R.5381: International Pharmaceutical Transparency Act of 2019.
Drug Compounding.
Drug Shortages.
Product Hopping.
H.R.4398: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019.
Biosimilars Naming.
Biosimilars Insulin.
Pass Through Payments for Biosimilars.
S.1140: Protecting Access to Biosimilars Act of 2019.
H.R.4455: BIOSIM Act.
H.R.4597: Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R.4629: Star Rating for Biosimilars Act.
Prescription Drug Costs.
Drug Pricing.
American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
FDA Citizen Petitions.
H.R.2387: STOP GAMES Act of 2019.
H.R.1506: FAIR Generics Act.
H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
S.475: RxCAP Act of 2019.
180-Day Exclusivity.
H.R.2455/S.1169: Ensuring Timely Access to Generics Act of 2019.
S.3092: Expanding Access to Low-Cost Generics Act of 2019.
S.2543: Prescription Drug Pricing Reduction Act (PDPRA) of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
S.1416: Affordable Prescriptions for Patients Act of 2019.
H.R.2376: Prescription Pricing for the People Act of 2019.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019.
H.R.465/S.102: Prescription Drug Price Relief Act of 2019.
H.R.3: Lower Drug Costs Now Act of 2019.
S.1895: Lower Health Care Costs Act.
S.1805: Better Tools for Healthy Living Act.
H.R.965/S.340: CREATES Act of 2019.
Public Law 115-123: Bipartisan Budget Act of 2018.
Risk Evaluation and Mitigation Strategies (REMS).
Pharmaceutical Exclusivity.
30-Month Stays.
Biologic Exclusivity.
S.659: Biologic Patent Transparency Act.
Biologics Price Competition and Innovation Act (BPCIA).

Lobbyists (11)
  • CHRISTINE SIMMON
  • CHESTER DAVIS JR
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • JOSEPH STEWART
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Commerce, Dept of (DOC)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 5
Taxation/Internal Revenue Code

User Fee Programs.

Lobbyists (6)
  • CHRISTOPHER BOWLIN
  • DAVID R. GAUGH
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JOSEPH STEWART
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Commerce, Dept of (DOC)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 6
Trade (domestic/foreign)

General Trade Issues.
Trans-Pacific Partnership (TPP).
Biologic Exclusivity.
Pharmaceutical Exclusivity.
United States-Mexico-Canada Agreement (USMCA).
North American Free Trade Agreement (NAFTA).
U.S.-UK Trade Agreement.
U.S.-India Trade Discussions.
U.S.-European Trade Negotiations.
U.S.-China Trade Negotiations.
Secretary Azar Importation Plan.

Lobbyists (9)
  • CHESTER DAVIS JR
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • JOSEPH STEWART
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Commerce, Dept of (DOC)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.